Daré Bioscience, Inc. reported a significant decline in revenue for the third quarter of 2025, with total revenue of $2,262, a decrease of 95% compared to $41,691 in the same period of 2024. For the nine months ending September 30, 2025, the company generated $6,517 in revenue, down 91% from $73,431 in the prior year. The sharp decline in revenue is attributed to the transition of royalty revenue from its license agreement with Organon for the commercialization of XACIATO, which is now recognized as non-cash royalty revenue following a royalty purchase agreement with XOMA that took effect in April 2024.
Operating expenses for the third quarter decreased by 22% to $3,674,410 from $4,723,040 in the previous year, primarily due to a 56% reduction in research and development expenses, which fell to $1,175,168 from $2,681,772. General and administrative expenses increased by 22% to $2,499,242, reflecting higher professional services and commercial-readiness costs associated with the company's expanded business strategy. The net loss for the quarter was $3,562,766, a 24% improvement from the loss of $4,702,501 reported in the same quarter of 2024.
In terms of strategic developments, Daré Bioscience is shifting its business model to include a dual-path approach for product commercialization. This includes pursuing both traditional FDA approval and earlier market access through Section 503B compounding. The company plans to launch its first product under this new strategy, DARE to PLAY Sildenafil Cream, in December 2025. This product aims to address female sexual arousal disorder and will be available through licensed prescribers and telehealth platforms.
Operationally, the company reported a cash position of approximately $23.1 million as of September 30, 2025, with a working capital of about $3.8 million. The majority of the cash is tied to grant agreements, which may only be used for specific project costs. Daré's accumulated deficit reached approximately $187.2 million, and the company incurred a net loss of about $12 million for the nine months ended September 30, 2025. The company anticipates needing additional capital to support its development programs and operational plans, with potential funding sources including equity sales, debt financing, and government grants.
Looking ahead, Daré Bioscience faces uncertainty regarding its ability to generate sufficient revenue to sustain operations. The company has expressed substantial doubt about its ability to continue as a going concern within the next 12 months, emphasizing the need for strategic capital-raising efforts to support its product development and commercialization initiatives.
About Dare Bioscience, Inc.
Dare Bioscience Inc. develops innovative women’s health solutions, including prescription and compounded products for contraception, sexual health, menopause, and vaginal health. Its portfolio features FDA-approved XACIATO for bacterial vaginosis and pipeline candidates like Ovaprene, Sildenafil Cream, and DARE-HRT1, targeting unmet needs in fertility, VMS, and FSAD. The company leverages clinical data, strategic collaborations, and alternative pathways to bring evidence-based, first-in-category products to market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.